British med-pot company GW Pharmaceuticals is moving into Phase III clinical trials of a sublingual spray which uses cannabis extracts. They hope to market them for medical use by 2003.
GW Pharmaceuticals has also gone public with a listing on the London Stock Exchange, raising about 25 million pounds ($35 million US) from their initial sale of stock, about $12 million more than expected.
In May, Reuters reported that GW Pharmaceuticals chairman, Dr Geoffrey Guy, had received approval from Health Canada to start clinical trials in that country.
– website www.gwpharm.com
